Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine
The Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine (an Open-label, Randomised, Single-dose, Two-way Crossover Study)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 1
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Healthy males according to the following criteria:
Based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
1.1 No finding deviating from normal and of clinical relevance
1.2 No evidence of a clinically relevant concomitant disease
- Age ≥21 and Age ≤55 years
- BMI ≥18.5 and BMI < 30 kg/m2 (Body Mass Index)
- Resting pulse rate (PR; after 10 min. in the supine position) of more than 55 bpm
- Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
Exclusion Criteria:
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, ophthalmological, or hormonal disorders
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts.
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial.
- Participation in another trial with an investigational drug within two months prior to administration or during the trial
- Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)
- Inability to refrain from smoking on trial days
- Alcohol abuse (more than 60 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- Excessive physical activities (within one week prior to administration or during the trial)
- Any laboratory value outside the reference range that is of clinical relevance
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Cilobradine, low dose plus itraconazole
Pre-study
|
Andre navne:
|
|
Aktiv komparator: Cilobradine, low dose
Pre-study
|
|
|
Eksperimentel: Cilobradine, high dose plus itraconazole
main study
|
Andre navne:
|
|
Aktiv komparator: Cilobradine, high dose
main study
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
|
Maximum measured concentration of the analyte in plasma (Cmax)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
|
|
Time from dosing to Cmax (Tmax)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
|
|
Terminal rate constant in plasma (λz)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
|
|
Terminal half-life of the analyte in plasma (t1/2)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
|
|
Mean residence time of the analyte in the body after p.o. administration (MRTpo)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
|
|
Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
|
|
Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)
Tidsramme: up to 56 hours after administration of Cilobradine
|
up to 56 hours after administration of Cilobradine
|
|
|
Amount of parent compound excreted in urine with zero to 72 h in % of dose (fe0-tz)
Tidsramme: up to 72 hours after administration of Cilobradine
|
up to 72 hours after administration of Cilobradine
|
|
|
Renal clearance of cilobradine (CLR,0-tz)
Tidsramme: up to 72 hours after administration of Cilobradine
|
up to 72 hours after administration of Cilobradine
|
|
|
Number of subjects with adverse events
Tidsramme: up to 46 days
|
up to 46 days
|
|
|
Occurrence of visual phenomena
Tidsramme: up to 46 days
|
questionnaire
|
up to 46 days
|
|
Number of subjects with clinically relevant findings in vital signs
Tidsramme: up to 32 days
|
blood pressure, pulse rate
|
up to 32 days
|
|
Number of subjects with clinically relevant findings in laboratory tests
Tidsramme: up to 32 days
|
up to 32 days
|
|
|
Number of subjects with clinically relevant findings in 12-lead electrocardiogram
Tidsramme: up to 32 days
|
up to 32 days
|
|
|
Assessment of tolerability by investigator on a 4-point scale
Tidsramme: within 8 days after last PK sampling
|
within 8 days after last PK sampling
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Enzymhæmmere
- Hormoner, hormonsubstitutter og hormonantagonister
- Cytokrom P-450 CYP3A-hæmmere
- Cytokrom P-450 enzymhæmmere
- Hormonantagonister
- Antifungale midler
- Steroidsyntesehæmmere
- 14-alfa-demethylasehæmmere
- Itraconazol
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 503.213
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .